Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02BRJ
|
|||
| Former ID |
DIB010659
|
|||
| Drug Name |
Vabicaserin
|
|||
| Synonyms |
Vabicaserin hydrochloride; PF-05208769; PF-5208769; SCA-136; WY-16629
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Phase 2 | [1] | |
| Company |
Wyeth
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H20N2
|
|||
| Canonical SMILES |
C1CC2CN3CCNCC4=C3C(=CC=C4)C2C1
|
|||
| InChI |
1S/C15H20N2/c1-3-11-9-16-7-8-17-10-12-4-2-5-13(12)14(6-1)15(11)17/h1,3,6,12-13,16H,2,4-5,7-10H2/t12-,13-/m0/s1
|
|||
| InChIKey |
NPTIPEQJIDTVKR-STQMWFEESA-N
|
|||
| CAS Number |
CAS 887258-95-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2B receptor (HTR2B) | Target Info | Modulator | [2], [3] |
| 5-HT 2C receptor (HTR2C) | Target Info | Modulator | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00768612) Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia. U.S. National Institutes of Health. | |||
| REF 2 | Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111. | |||
| REF 3 | Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther. 2011 Jun;337(3):673-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.